Bristol Launches Zeposia For MS, Sees Advantages In The COVID-19 Environment
After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.
You may also be interested in...
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.
Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.
Ponesimod is the fourth S1P modulator approved to treat multiple sclerosis and joins a sprawling class of oral and injectable therapies. But Janssen sees numerous ways to differentiate its drug.